Cardiology

An artificial intelligence can detect increased fluid in lungs by simply hearing voice changes over time—and the increased fluid in lungs can be a sign of heart failure.

Compared to their usual diet, participants placed in the low sodium diet group—required to keep their sodium intake to 500 mg daily—had their blood pressure reduced by 6 mm Hg.

FDA approved sotaglifozin (INPEFA®) on May 26, 2023, to treat heart failure. Also, a phase 3 trial shows the clinical benefits of the drug by the 3-month mark.

Results of ARIES-HM3 demonstrate use of aspirin was associated with an increased rate of major bleeding following HeartMate 3 implantation.

In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.

Early control of blood pressure helps lower blood pressure levels in postpartum women and potentially slows the progression of needing treatment for hypertension later down the line.

Presented at AHA 2023, phase 1 data for lepodisiran showcased a 97% reduction in lipoprotein(a) levels at the 608 mg dose.

Participants with heart failure measured lower on physical and mental component scores than patients with lung, colon, breast, or prostate cancer, highlighting their worser health-related quality of life.

Lowering blood pressure significantly reduced the risk of developing dementia among adults with hypertension in China compared to usual care.

The incidence of hypertensive disorders of pregnancy rose from 9.22% in January 2018 to 12.15% in December 2021.

The phase 2 KARDIA-1 study reports a single dose of zilebesiran safely reduced systolic blood pressure in people with mild-to-moderate hypertension for up to 6 months.

Results of the ARTESIA trial suggest apixaban lowered stroke risk by 37% in subclinical atrial fibrillation versus aspirin, but increased major bleeding risk.

Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.

Brendon Neuen, MBBS, PhD, discusses the results of a study he presented at AHA 2023 estimating the lifetime benefit of combination therapy in patients with type 2 diabetes and albuminuria.

New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.

ORBITA-2 trial: Percutaneous coronary intervention improved chest pain and quality of life vs. placebo in stable angina patients.

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.

The MINT trial, which included 3504 patients with acute MI and anemia, shows a trend favoring liberal transfusion, indicating a potential for improved outcomes.

In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.

Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.

Marc Bonaca, MD, discusses an AHA 2023 study he led examining trends in discordance between LVEF and ICD-10 codes used in heart failure hospitalizations.

Paul Ridker, MD, MPH, discusses the evolving recognition of the role inflammation plays in driving cardiovascular risk among patients with atherosclerosis.

On November 7, 2023, Recor Medical announced the FDA approval of their Paradise Ultrasound Renal Denervation system for the treatment of hypertension.

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.